Rafferty Asset Management
MCRB icon

Rafferty Asset Management’s Seres Therapeutics MCRB Stock Holding History

Rafferty Asset Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-46,819
Closed -$2.23M – 1089
2023
Q3 		$2.23M Buy
46,819
+8,150
+21% +$622K 0.01% 580
2023
Q2 		$3.7M Buy
38,669
+26,705
+223% +$2.91M 0.02% 482
2023
Q1 		$1.36M Sell
11,964
-3,912
-25% -$423K 0.01% 720
2022
Q4 		$1.78M Buy
15,876
+5,646
+55% +$757K 0.01% 610
2022
Q3 		$1.31M Buy
+10,230
New +$1.05M 0.01% 598
2022
Q2 		– Sell
-14,822
Closed -$2.11M – 1187
2022
Q1 		$2.11M Sell
14,822
-1,677
-10% -$258K 0.01% 589
2021
Q4 		$2.75M Sell
16,499
-8,349
-34% -$1.33M 0.01% 557
2021
Q3 		$3.46M Buy
24,848
+18,498
+291% +$3.62M 0.02% 405
2021
Q2 		$3.03M Sell
6,350
-1,446
-19% -$610K 0.02% 498
2021
Q1 		$3.21M Buy
7,796
+5,881
+307% +$2.71M 0.02% 444
2020
Q4 		$938K Buy
+1,915
New +$1.12M 0.01% 519

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rafferty Asset Management's MCRB Position: Q4 2023 in Review

Rafferty Asset Management sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 46,819 shares — an estimated $2.23M sold.

Rafferty Asset Management first reported a position in MCRB in Q4 2020 and held it in 11 quarters. The position peaked at $3.7M in Q2 2023. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

  • Rafferty Asset Management reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Rafferty Asset Management sold 46,819 Seres Therapeutics shares in Q4 2023, an estimated $2.23M.
  • Rafferty Asset Management first reported a position in Seres Therapeutics in Q4 2020 and held it in 11 quarters.
  • Rafferty Asset Management's Seres Therapeutics position peaked at $3.7M in Q2 2023.
  • 102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on Rafferty Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.